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Abstract: The purpose of this study was to describe the distribution of serum prostate specific antigen (FSA) 
and to determine age-specific reference range in a population of Persian men. Venous blood samples were taken 
from 287 men, from Gorgan located in the North of Iran, South-East of Caspian Sea, aged 15~80 year. The serum 
FSA levels was measured using Enzyme-linked Irnmllllosorbant-Assay (ELISA) technique and age-specific 
range for FSA level was determined. The serum prostate-specific antigen level for six age group of 15-40 years, 
41-50 years, 51-60 years, 61-70 years, 71-80 years and >80 years were mainly in the range of0-2.5 ng mL -', 
for76.6%, 2.6-4ng mL-l for9.l % and as whole 85.7% of all men in this study had <;4ngmL-', 8.7 and5.6% all 
men of six age group had FSA level of 4.1-10 ng mL-i and>10 ng mL - 1, respectively. The findings of present 
study indicated that a large proportion (76.6%) men in this region have a lower FSA level of 0-2.5 ng mL -l and 
only 9.1 % of men have FSA level of 2.6-4 ng mL -l. It is therefore concluded that acceptable reference range of 
0-4 ng mL -l for FSA level require further reassessment. 
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INTRODUCTION 	 that a normal FSA level can not exclude the presence of 
prostate on biopsy. In an another study it has been 
Prostate cancer has the highest incidence among male reported that men below 60 years of age with base line 
malignancies. Since the introduction of Prostate-Specific FSA level of 0.6-2.5 ng mL -l are at greater risk of 
Antigen (FSA) testing in the late 1980s, the incidence of having prostate than those men with a baseline FSA level 
prostate cancer has increased, with a change toward <0.6 ng mL -l (Loeb et al., 2005). 
detecting it an early stage (Jemal et al., 2004; Mellin and In a further study, it was also shown that a base line 
Murphy, 1996). Age-specific reference ranges for serum FSA level above the age-adjusted ( 40-49, 50-59, >60 years) 
FSA levels is established to improve it's sensitivity in median levels of 0.7, 0.9, 1.4 ng mL-l represents a 
yollllger men and to increase it's specificity in older men significant risk factor for developing prostate cancer 
(Oesterling et al., 1993), this later researcher suggested (Kundu et al., 2005). 
upper range reference value of 2.5, 3.5, 4.5 and 6.5 ng mL -l Several studies have also demonstrated that a 
for the age decades of 40-49, 50-60, 60-69 and 70-79 years substantial number of men have microscopic evidence of 
in asymptomatic men with no clinical evidence of prostate prostate cancer despite having a prostatic specific antigen 
cancer. In spit of these findings, recent investigations (FSA) level below 4 ng mL -l the standard threshold used 
emphasize the limitation of these FSA threshold value to define abnormal. 
to discriminate between prostate cancer and benign The findings from such investigation have led some 
disease, in asymptomatic men (Thompson et al., 2004; physicians to look more carefully at a lower FSA 
Loeb et al., 2005; Kundu et al., 2005). threshold of 2.5 ng mL-l (Thompson et al., 2004; 
It is reported that the prostate cancer was detected in Raaijmakers et al., 2004; Catalana et al., 1997), using this 
15.2% of men whose total FSA level was <4 ng mL - 1, FSA level means that more men than before would be 
which is the threshold for diagnosing prostate cancer labeled as a abnormal and therefore are being looked more 
(Thompson et al., 2004), also it has been reported that, deeply and tested for prostate cancer. In this study it was 
despite very low level FSA levels of 0.1-1.0 ng mL-1 as tried to establish the FSA level in a various age groups of 
many as 16.7% of those men had prostate cancer on men, in Gorgan the capital city of Golestan Province in the 
biopsy (Thompson et al., 2004). These later data indicate South-east Caspian Sea of northern Iran. 
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The aim of this study was to determine age-specific 
reference ranges for serum FSA levels inmen aged 15-~80 
years of age in this region. 
MATERIALS AND METHODS 
This study was carried out on 287 men whom referred 
to Danesh medical diagnostic laboratory, for Prostate­
Specific Antigen (FSA) testing for a period of one year 
September 2005-0ctober 2006. Data on the distribution of 
FSA level for the above sample population were obtained, 
using venous blood samples which were taken from the 
above number of men, whom mainly were resided in this 
cosmoplitant region which is the Capital city of Golestan 
Province in the north of Iran, located in the South-East 
of Caspian Sea. Total serum FSA levels were measured 
using Enzyme-Linked Immunosorbant Assay (ELISA) 
technique. The basis for this procedure was a sandwich 
method using monoclonal, antibodies against the FSA 
molecules specific antigenic part. The samples serum were 
placed into wells which was covered by the FSA 
antibodies. After incubation and subsequent washing the 
chromagen was added. The reaction was stopped 
afterward and the colored solution absorbance in the 
wells, were read using an ELISA reader (Belanger et al., 
1996; Zhov et al., 1993), serum samples were aliquoted in 
2 mL batches in freezer, in the early morning and stored 
until analysis of PSA determination was carried out in few 
hours time. 
RESULTS 
In this study, the FSA determination was carried out 
on the six age groups as follow: 15-40 years, 41-50 years, 
51-60 years, 61-70 years, 71-80 years and more than 
80 years. The results of FSA determination for the 
above age group were presented in Table 1. The FSA 
determination for each group were subdivided the 
following range of PSA concentration 0-2.5 nanogram per 
milliliter (ng mL _,), 2.6-4, 4.1-10and>10 ng mL _,_ 
The men in 15-40 years, 41-50 years, 51-60 years, 
61-70 years, 71-80 years and more than 80 years age 
groups had the following ratio of distribution 5.2, 20.6, 
26.1, 27.8, 16.7 and3.5%, respectively. The results from 
Table 1: PSA level distribution among men subjects in different age group 
Age group (year) PSA 0-2.5 (ngmL-1) PSA 2.6-4(ngmL-1) PSA 4.1-10 (ng mL-1) PSA>lO(ngmL-1) Total No. 
15-40 15 (100%) 15 (5.2%) 
41-50 54 (91.5%) 4 (6.7%) 1 (1.7%) 59 (20.6%) 
51-60 56 (74.6%) 8 (10.6%) 7 (9.3%) 4 (5.3%) 75 (26.1%) 
61-70 58 (72.5%) 8 (10%) 10 (12.5%) 4(5%) 80 (27.9%) 
71-80 30 (62.5%) 5 (10.4%) 6 (12.5%) 7 (14.5%) 48 (16.7%) 
>80 7 (7lf'/o) 1 (10%) 2 (20%) 10 (3.5%) 
Total 220 (766%) 26 (9.1%) 25 (8.7%) 16 (5.5%) 287 
Table 1 was also indicated that 76.6, 9.1, 8.7 and 5.5% of 
all the sample population in the above age groups in 
this study had the following PSA level<; 2.5, ~ 2.6-4 <;, ~ 
4.1-10 and >10 ng mL - 1, respectively. The result in 
Table 1 showed that in 15-40 years age group, 100% of 
men having serum FSA level 0-2.5 ng mL - 1, in 41-50 years 
age group 91.5, 6. 7 and 1. 7% of all men in this group 
had the PSA level, of 0-2.5, 2.6-4 and > 10 ng mL -', 
respectively. In 51-60 years age group, 74.6, 10.6, 9.3 and 
5.3% of all men. In this age group had, the PSA level of 
0-2.5, 2.6-4, 4.1-10 and >10 ng mL-', respectively. In 
61-70yearsagegroup72.5,10, 12.5 and 5% of all men 
in this age group had the PSA level of0-2.5, 2.6-4, 4.1-10 
and>10 ng mL - 1, respectively. 
In 71-80 tears age group, 62.5, 10.4, 12.5 and 
14.5% of all men in this age group had the PSA level 
of 0-2.5 ng mL-',2.6-4ngmL-',4.l-10ngmL-'and 
>1Ong mL-l, respectively and finally in >80 years age 
group, 70, 10 and 20% of all men in this age group had the 
PSA level of 0-2.5, 2.6-4 ng mL-' and 4.1-10 ng mL -', 
respectively. 
In this study 85. 7% all sample population in all of the 
six age groups had the serum FSA level :::;4 ng mL -l which 
is an permitable threshold for the excluding prostate 
abnormalities by the present FSA reference range. 8. 7% of 
all men in this study had the PSA level of 4.1-10 ng mL _, 
and also 5.6% of all men in this study had the PSA level 
more than 10 ng mL -l which in both cases further medical 
investigation were required, by the present standard 
(Table 2). 
Also in the Table 2 subjects with :::; 2.5 ng mL -l of 
FSA level shoV\Tll to be 76.6% of all men in this present 
study. 
In this study, we also arranged the results for all six 
age groups ofl5-40, 41-50, 51-60, 61-70, 71-80 and>80 
years of age individually on the basis of0.5, 1, 1.51, up to 
9.5 ng mL - 1, lOng mL-l and>lOwas presented in Table 
3, which showed the distribution of Prostate-Specific 
Antigen (PSA) level among the sample population in this 
study, by 0.5 ng mL _, PSA level increase. 
According to present findings it is indicated that 
7 6.6% of all men in this investigation had FSA level 
up to 2.5 ng mL_, and 9.1 % of men had PSA level of 
2.6-4 ng mL -l which is still considered to be normal (i.e., 
:::;4 ng mL - 1) but further, it can be seen from the above 
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Table 2: PSA level distribution among men subjects regardless of age group 
PSA level (ng mL-1) Number (men) Percentage 
~ 2.5 220 76.6 
,4 246 85.7 
4.1-10 25 8.7 
>10 16 5.6 
Table 3: Distribution of serum Prostate-Specific Antigen (ESA2 level by 0.5 ng mL-1 increase among men undergone in this study 
Prostate-Specific Antigen (PSA) ng mL-1 
Age group Total ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
(year2 men 0.5 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10 ,10 
15-40 15 53% 27% 7% 13% 
41-50 59 27.5% 32.7% 25.So/o 6.So/o 5% 1.7% 1.7% 
51-60 75 25.3% 24% 16% 12% 2.6% 2.6% 4% 4% 2.6% 1.3% 2.6% 2.6% 
61-70 80 19.2% 20.5% 17.gJ/o 10.2% 6.4% 5.1% 1.2% 3.So/o 3.So/o 1.2% 1.2% 1.2% 1.2% 1.2% - 5% 
71-80 48 8.3% 18.7% 14.5% 14.5% 6.3% 4% 4% 2% 6.3% - 2.1% 2.1%- 14 . .SO/o 
>80 10 40% 300/o 100/o 100/o 10% 
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datas that only 8.7% of all men had FSA level of 
4.1-lOngmL-' and 5.5% of all men had FSA level of 
>10 ng mL-l which in both cases considered to be 
abnormal and needed further medical following-up. 
DISCUSSION 
Most men have a serum FSA level of:::; 4 ng mL -l and 
this value rise steadily with age, which had been reported 
in number of studies including (Gilbert Welch et al., 2005; 
Elijah et al., 2005), which indicated that there is a 
significant correlation between men age and total FSA 
level. In the era of predominantly impalpable prostate 
cancer, FSA represents the main indicator of the 
likelihood of harboring prostate cancer, however the best 
threshold value has been disputed and revised by several 
investigator, some showed an identical prostate cancer 
detection rate in men with FSA level of 2.5-4 ng mL - 1, as 
in those with levels of 4-10 ng mL _, (Catalom et al., 1991; 
Schroder et al., 2000; Ladding et al., 1998). However a 
universal threshold value dose not represent a valid risk 
stratification for all men, regardless of age (Catalana et al., 
1991; Schroader et al., 2000; Ladding et al., 1998) 
therefore, efforts were made to improve the sensitivity and 
specificity of FSA level threshold. 
Age-specific FSA reference ranges of 0-2.5, 0-3.5, 
0-4.5 and 0-6.5 ng mL _, for age categories. 40-49, 50-59, 
60-69 and 70-79 years in asymptomatic healthy men at risk 
were proposed (Oesterling et al., 1993). 
The correlation between men subjects with age and 
total FSA level is also reported in other reviews 
(Dalkine et al., 1993; Oesterling et al., 1993; Collins et al., 
1993). 
However, recent findings indicate that these 
reference range might need to be revised due to limited 
sensitivity and to an excessive proportion of false­
negative results (Thompson et al., 2004; Loeb et al., 2005; 
Kundu et al., 2005). 
As far as there was not any report on the reference 
range limited value of prostate specific antigen in this 
area, we decided to explore FSA levels in this region 
which is mainly a cosmoplitant society, in the north of 
Iran, South-east of Caspian Sea. 
Present finding in Table 1 indicated that the threshold 
of 100, 91.5, 75.6, 72.5, 62.5 and 70% of all men for the 
following age groups of 15-40, 41-50, 51-60, 61-70, 
71-80 and>80 years hadPSA level of <;2.5 ng mL -',which 
was partly similar to a separate study in USA (Gilbert 
Welch et al., 2005), where it was reported that Frostate­
Secific Antigen (FSA) level of <4 ng mL - 1, nonetheless 
have microscopic evidence of prostate cancer has led to 
some investigations that the threshold defining abnormal 
should be lowered to 2.5 ng mL _,. In USA study it 
was concluded that, lowering the FSA threshold to 
2.5 ng mL -l would double the number of men defined as 
abnormal (Gilbert Welch et al., 2005). In this study the 
proportion of population affected by different thresholds 
would vary with age, among men of 15-40 years of age 
non of the menhadPSA level more than 2.5 ng mL _,_ 91.5, 
6.7and1.7% ofmen in their40s hadPSA level <;2.5, >2.5-4 
and>lOngmL-', 74.6, 10.6, 9.3 and 5.3% of men in their 
50s had FSA level of <; 2.5, >2.5-4 <; and>10 ng mol-', 
72.5, 10, 12.5 and 5% of men in their 60s had FSA level 
of <;2.5, >2.5-4 '· >4.1-10 <; and>10 ng mL -', 62.5, 10.4, 
12.5 and 14.5% of men in their 70s had FSA level 
of <;2.5ngmL-',>2.5-4<; ng mL-', 4.1-10<; ng mL-' and 
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> 10 ng mL _, and finally, 70, 10 and 20% in their 80s had 
FSA level of <;2.5 ng mL _, >2.5-4 <; ng mL -', >4.1-10 <; ng 
mL_,. In another study (Porter et al., 2006) the men for 
example in their 60s, 17% of men had FSA level over 2.5 
ng mL_, 5.7% had FSA level of 4 ng mL _,and 1.7% had 
a FSA level over 10 ng mL -i which was partly similar to 
present study. Present study about the correlation of age 
and total FSA level are also cofirrned by other studies 
(Oesterling et al., 1993; Daklin et al., 1993; Collins et al., 
1993). 
In this study, 85.7% of all men had the FSA level 
:::; 4 ng mL-i which is normal level according to the 
definition for the FSA level it means that in our study 
85.6% ofall men have normal FSA level and only 14.4% of 
men have FSA level more than 4 ng mL-i and these men 
considered to be at risk and needed to be followed up for 
further investigation but there are some report which 
indicated that a lorge number of prevalent cases of biopsy 
detectable prostate cancer exist in men with a normal FSA 
level (Porter et al., 2006), therefore for the men with normal 
FSA level in our study it should be a nesecity to look for 
any clinical indication of prostate abnormality. 
There is a study which was reported that 15.2% of 
449 men with FSA level of <4 ng rnL-l were found to have 
prostate cancer (Thompson et al., 2004), with an even 
distribution across age groups. The mean FSA in our 
study was 1. 72 ng mL -l which was little more than above 
study. In the above study (Thompson et al., 2004) it was 
reported that the trial data showed that all patients with 
detected prostate cancer, 337 men (67 .8%) had base line 
FSA levels above the mean FSA level of 1.34 ng mL _,_ In 
a recently reported large screening population of 14000 
men aged <60 years an initial base line FSA level of 
0.6-2.5 ng mL -l was associated with a greater risk of 
developing prostate cancer (Loeb et al., 2005). In another 
study it was indicated that a FSA level is directly 
correlated with age and showed that FSA level of 
2.6-4 ng mL -l increased the risk of prostate cancer for 
each of the studied age group of 40-49, 50-59 and >60 
years, but this effect was most pronounced in yollllger 
men aged 40-49 years (Kundu et al., 2005). In another 
study (Oesterling et al., 1993) it was showed that the 
FSA level increase by age. In this study we did have 
FSA level maximum of up to 2.5 and 3.5 ng mL _,for the 
aged group of 15-40 and 41-50 years. The FSA level 
increase for the age group of 51-60 year to about 
5.5 ng mL-1 also 1.7% of men in this age group had FSA 
level of>10 ng mL _,. In the age group of 61-70 years of 
age, the FSA level raised up to 7 ng mL -l also we had 
2.6% of men in this age group to have the FSA level 
>10 ng mL _,. In the age group 71-80 years the FSA level 
increased up to 8 ng mL -l in here also we had 5% of men 
in this age group with FSA>10 ng mL - 1. 
In this study in age group of >80 years also we had 
FSA level >10 ng mL-l for 14.5% of men in this 
group, but 70% of men of >80 year had FSA level of up to 
1 ng mL - 1, but it should be mentioned that the number 
men in this a group was only 10 men: (Table 3). The data 
from this present study indicated that as in the earlier 
reports in various part of the world the serum FSA levels 
are age dependent, there are numerous studies in this 
regard. (Oesterling et al., 1993; Loeb et al., 2005; Gilbert 
Welch et al., 2005; Elijah et al., 2005; Ladding et al., 1998; 
Veltri et al., 2002). 
In conclusion the present study is mrique in the 
origin of the population and among the conflicting reports 
of the FSA level which are considered for the detection of 
prostate cancer, the FSA level require reassessment for 
the different countries and even in one country with 
different ethnic groups where the detection of prostate 
cancer and its genetic make-up may differ from one 
another. 
The present study confirms earlier reports that serum 
FSA level are age-dependent, but also a big majority of 
men having FSA level of:::; 2.5 ng mL - 1. Therefore, it is 
appropriate to have age specific reference ranges for the 
age variable in various communities, this will enhance the 
positive predictive value of FSA estimation in the 
diagnosis of prostate cancer in each society. Further 
investigations in this region is required to obtain some 
datas about the correlation between serum FSA levels, 
prostate volume and race-dependentcy in this commmrity, 
which is a mrique multi-racial society, in the north of Iran. 
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